Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Current Deferred Revenue (2016 - 2025)

Spero Therapeutics' Current Deferred Revenue history spans 8 years, with the latest figure at $258000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 29.89% year-over-year to $258000.0; the TTM value through Dec 2025 reached $258000.0, down 29.89%, while the annual FY2025 figure was $258000.0, 29.89% down from the prior year.
  • Current Deferred Revenue reached $258000.0 in Q4 2025 per SPRO's latest filing, down from $5.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $27.1 million in Q2 2024 to a low of $258000.0 in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $8.6 million, with a median of $6.9 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: plummeted 82.74% in 2024, then surged 500.87% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.9 million in 2021, then skyrocketed by 123.42% to $4.1 million in 2022, then crashed by 48.61% to $2.1 million in 2023, then tumbled by 82.74% to $368000.0 in 2024, then dropped by 29.89% to $258000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Current Deferred Revenue are $258000.0 (Q4 2025), $5.4 million (Q2 2025), and $17.2 million (Q1 2025).